Pod Falar de Câncer, Sim! #108 Câncer de Intestino: Novos Tratamentos Que Estão Mudando a História

The treatment of bowel cancer has changed—a lot—in recent years. But what is already a reality in medical practice, and what is still under development? In this podcast episode, we welcome gastroenterologist Rodrigo Gomes (@rodrigo_gomes_dr) for a conversation about the advances that are transforming colorectal cancer care in 2026. We discuss new medications and targeted therapies that are already demonstrating an impact on patient survival, as well as the role of immunotherapy in this scenario. We also address an increasingly present question: will it be possible to transform metastatic cancer into a controllable condition in the long term? A necessary conversation to understand where oncology is heading. To watch the full podcast, access our YouTube channel. Link in bio. #bowelcancer #colorectalcancer #blueMarch #cancerprevention #colonoscopy #bowelhealth #oncology #preventivemedicine #talkaboutcanceryes Post in partnership with Libbs. The opinions expressed are those of the professional and do not necessarily reflect the institutional position of Libbs. Presenter: Name: Mariana Cunha CRM: CRMMG54475 Specialty: Clinical Oncologist Guest: Rodrigo Gomes da Silva CRM: 28351 Specialty: Coloproctologist 02:36 – In Brazil, data from INCA indicate that colorectal cancer is among the most incident, reflecting global trends of increase, especially in developing countries. This growth is associated with lifestyle changes, such as inadequate diet, sedentary lifestyle, and population aging. 03:17 – Institutional information reinforces that bowel cancer is a multifactorial disease, involving genetic and environmental factors, with generally slow progression from precursor lesions, such as polyps. 05:57 – International studies show inequalities in access to screening, highlighting that socioeconomic factors directly impact participation in preventive programs and, consequently, clinical outcomes. 07:09 – American Cancer Society guidelines recommend initiating screening in average-risk adults starting at age 45, emphasizing the importance of early detection. 10:26 – Recommendations from US task forces reinforce the use of methods such as colonoscopy and fecal tests, with individualized strategies according to patient risk. 12:20 – Scientific evidence indicates that a diet rich in fiber, fruits, and vegetables has a protective effect, while inadequate dietary patterns increase the risk of colorectal cancer. 15:37 – Consumption of ultra-processed foods is associated with a higher risk of cancer, reinforcing the importance of diet quality in prevention. 16:54 – International reports highlight that adequate nutrition and regular physical activity are fundamental pillars in reducing the risk of the disease. 17:43 – Epidemiological data show changes in incidence patterns over the decades, including an increase in younger populations. 19:02 – Clinical guidelines guide the management of colon cancer based on staging, including surgery and systemic therapies. 20:34 – Genomic studies identify different molecular subtypes of colorectal cancer, allowing for more personalized treatment approaches. 22:15 – European consensus guides the treatment of metastatic cancer with combined and individualized strategies. 22:59 – Reinforcement of ESMO guidelines highlights the importance of a multidisciplinary approach in advanced treatment. 25:14 – Comprehensive reviews describe colorectal cancer as a heterogeneous disease, with multiple factors involved in its progression. 29:02 – Classic surgical references detail the technical principles of treatment, including resections and appropriate oncological management. 32:58 – Recent studies evaluate complications and rates of permanent ostomy after different surgical approaches, including minimally invasive techniques. 35:17 – Clinical guidelines address the management of patients with ostomies, emphasizing quality of life care. 38:18 – USPSTF recommendations reinforce screening as an essential strategy for reducing mortality. 41:08 – Meta-analyses demonstrate good accuracy of fecal immunological tests as a non-invasive screening tool. 43:44 – Recent research explores vaccines targeting mutations such as KRAS, showing promising results in treatment. 46:47 – Studies with immunotherapy, such as PD-1 blockade, show significant responses in patients with DNA repair deficiencies, opening new therapeutic perspectives.